Please login to the form below

Not currently logged in
Email:
Password:

Crisaborole

This page shows the latest Crisaborole news and features for those working in and with pharma, biotech and healthcare.

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Crisaborole is currently under FDA review. Late stage deals are not, however, a complete panacea. ... Corporate acquisition. Acquisition for $99.25 per share [55% premium], includes crisaborole under FDA review for mild to moderate eczema; est peak sales

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...